Relation Between White Blood Cell Count and Final Infarct Size in Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the INFUSE AMI Trial)

The contemporary value of peak creatine kinase‐MB after ST‐segment elevation myocardial infarction above other clinical and angiographic characteristics in predicting infarct size, left ventricular ejection fraction, and mortality

“…In this study multiple regression analysis peak CK‐MB, final MBG 0 or 1, and age were independent predictors of LVEF. In a similar substudy of the same trial, high leukocyte count at presentation, together with age, total abnormal wall motion score, time from symptom onset to first device, proximal left anterior descending location, and poor TIMI flow at baseline have also been reported as independent predictors of infarct size . In the INFUSE‐AMI substudies, R 2 of the multivariable models have not been reported, and direct comparison of the explained variance with the current study is therefore not possible.…”

CAMI-NSTEMI Score ― China Acute Myocardial Infarction Registry-Derived Novel Tool to Predict In-Hospital Death in Non-ST Segment Elevation Myocardial Infarction Patients ―

“…WBC count was previously reported to be associated with adverse events in AMI patients, including heart failure, cardiac shock, 12 and death, 13 as well as infarct size on magnetic resonance imaging. 14,15 The association, however, was not found to be significant at either 1-month or 1-year follow-up. Table S3).…”

Arctigenin exerts protective effects against myocardial infarction via regulation of iNOS, COX‑2, ERK1/2 and HO‑1 in rats

“…Despite the common therapeutic strategy of timely ischemic myocardial perfusion recovery, 25% of patients with AMI will develop chronic cardiac failure as a result of reperfusion injury (15). Reperfusion injury is a key factor for myocardial injury associated with myocardial infarction recanalization; therefore, reducing reperfusion injury is conducive to myocardial cell survival, reducing the loss of myocardial function and reducing the probability of developing chronic cardiac failure (16). In the present study, treatment with arctigenin significantly lowered the AMI-induced levels of ALT, CK-MB and LDH, and reduced the infarct size in AMI model rats.…”